SCHEMBL20652972

SCHEMBL20652972

CC(C)n1c(=O)[nH]c(=O)c2c1nc(-c1ccc(F)nc1F)n2Cc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.50
▸ BRDT Q58F21 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ POLB P06746 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ GAA P10253 2/20 0.42
▸ TYMS P04818 1/20 0.41
▸ TPH1 P17752 2/20 0.40
▸ TPH2 Q8IWU9 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652781 0.92 ALDH1A1 (0.54) SMN1; SMN2KDM4EPOLBALDH1A1MEN1
SCHEMBL22105376 0.85 TP53 (0.49) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL20653046 0.82 KDM4E (0.49) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL20656204 0.81 ALDH1A1 (0.48) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL22105552 0.78 TPH1 (0.54) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL20652980 0.76 KDM4E (0.53) SMN1; SMN2KDM4EPOLBALDH1A1MEN1
SCHEMBL20652960 0.76 TP53 (0.42) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL22105713 0.75 ALDH1A1 (0.50) SMN1; SMN2KDM4EPOLBALDH1A1MEN1
SCHEMBL20652786 0.71 BRD4 (0.49) TP53BRDTSMN1; SMN2KDM4EPOLB
SCHEMBL20652780 0.70 KMT2A (0.37) TP53SMN1; SMN2KDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 TP53 4314/4885BRDT 3238/4885SMN1; SMN2 1063/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 TP53 4636/4885BRDT 3233/4885SMN1; SMN2 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback